Top Page
Pharma Mar SA
(BME:PHM)
Pharma Mar SA (PHM) vs. iShares MSCI Spain ETF (EWP)
Pharma Mar SA Business Overview & Revenue Model
Pharma Mar SA Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.75M | 174.85M | 158.15M | 196.34M | 229.83M | 269.96M |
| Gross Profit | 165.93M | 166.67M | 148.54M | 182.70M | 213.39M | 256.24M |
| EBITDA | 21.93M | 21.23M | 4.55M | 52.07M | 104.08M | 155.94M |
| Net Income | 19.88M | 26.13M | 1.14M | 49.36M | 92.86M | 137.26M |
Balance Sheet | ||||||
| Total Assets | 333.50M | 349.64M | 340.52M | 393.26M | 368.39M | 330.26M |
| Cash, Cash Equivalents and Short-Term Investments | 140.85M | 154.53M | 162.56M | 182.42M | 201.88M | 195.52M |
| Total Debt | 51.94M | 51.08M | 43.67M | 42.63M | 49.33M | 56.66M |
| Total Liabilities | 136.02M | 141.28M | 147.08M | 170.30M | 190.47M | 227.54M |
| Stockholders Equity | 197.47M | 208.36M | 193.44M | 222.96M | 177.92M | 102.72M |
Cash Flow | ||||||
| Free Cash Flow | -18.29M | -9.48M | -29.40M | 29.47M | 17.87M | 275.94M |
| Operating Cash Flow | -9.56M | 6.03M | -13.45M | 38.32M | 25.68M | 278.94M |
| Investing Cash Flow | 39.33M | 1.03M | -43.05M | 10.88M | 18.47M | -119.01M |
| Financing Cash Flow | -5.43M | -5.35M | -32.14M | -13.37M | -27.41M | -73.82M |
Pharma Mar SA Technical Analysis
Pharma Mar SA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.44B | 70.90 | 10.15% | 1.00% | 8.39% | 947.08% | |
52 Neutral | $7.39B | >-0.01 | -63.86% | 2.36% | 16.15% | 0.36% | |
| ― | €2.31B | 225.00 | 0.69% | 1.46% | ― | ― | |
| ― | €1.41B | 12.72 | 16.04% | 6.09% | ― | ― | |
| ― | €7.08B | 30.53 | 3.37% | ― | ― | ― | |
| ― | €242.56M | 22.19 | 5.11% | 1.65% | ― | ― | |
| ― | €2.75B | 20.16 | 25.24% | 1.38% | ― | ― |
Pharma Mar SA Corporate Events
Pharma Mar SA has completed its share buy-back program ahead of schedule, acquiring a total of 91,111 shares, which represents 0.5% of its share capital, for over 7.5 million euros. The completion of this program will lead to the amortization of these shares through a share capital reduction, and the resumption of operations under a liquidity contract with JB Capital Markets from June 23, 2025.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA announced the payment of a dividend from its share premium reserve, set to be distributed on June 27, 2025, at a net amount of 0.80 euros per share. This move reflects the company’s commitment to providing value to its shareholders and could enhance its market position by demonstrating financial stability and shareholder-friendly policies.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar S.A. held its Ordinary General Meeting of shareholders, where all proposals from the Board of Directors were approved by a sufficient majority. The outcomes of the meeting will be published on the company’s website within five days, reflecting the company’s commitment to transparency and shareholder engagement.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA announced that its Chairman and Chief Financial Officer will present to shareholders at the Ordinary General Meeting in Colmenar Viejo, Madrid. This meeting is significant for stakeholders as it provides insights into the company’s current operations and future strategies.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA announced positive results from the phase 3 IMforte study, showcasing the effectiveness of Zepzelca® (lurbinectedin) combined with atezolizumab as a first-line maintenance treatment for advanced-stage small cell lung cancer (SCLC). The study demonstrated significant improvements in progression-free and overall survival, marking a potential new standard in SCLC treatment. The results were presented at the ASCO meeting and published in The Lancet, with a marketing authorization application submitted to the European Medicines Agency.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA has reported on its share buy-back program activities conducted between May 19 and May 23, 2025. During this period, the company purchased a total of 6,500 shares at varying prices on the BME trading center. This buy-back initiative is part of the company’s strategy to stabilize its stock and potentially enhance shareholder value.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
PharmaMar has submitted a marketing authorization application to the European Medicines Agency for Zepzelca® in combination with atezolizumab for first-line maintenance treatment in adult patients with advanced-stage small cell lung cancer. This application is based on significant results from the Phase 3 IMforte trial, highlighting the potential impact on PharmaMar’s operations and its positioning in the oncology market.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA has reported on its recent share buy-back program activities conducted between May 12 and May 16, 2025. This initiative is part of the company’s strategy to stabilize its stock and potentially enhance shareholder value, reflecting a proactive approach to managing its market presence.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar S.A., along with its partner Adium Pharma S.A., has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) for the treatment of metastatic small cell lung cancer (SCLC). This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, reinforcing Pharma Mar’s position in the oncology market and providing a new treatment option for a particularly aggressive form of lung cancer.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA, in partnership with Adium Pharma SA, has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) to treat metastatic small cell lung cancer (SCLC) in adults. This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, highlighting its growing impact in cancer treatment markets, particularly in Latin America.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar S.A. has announced the convening of its Ordinary General Shareholders’ Meeting, scheduled for June 18, 2025, at the Villa de Colmenar Viejo Municipal Auditorium in Madrid. The meeting will address several key agenda items, including the approval of annual accounts, management reports, and a proposal for dividend distribution. Additionally, the re-election of a director and the approval of a new share delivery plan for employees are on the agenda, indicating the company’s focus on strategic governance and employee engagement.
PharmaMar Group reported a 19% increase in recurring income, reaching 37.8 million euros in Q1 2025, driven by strong sales of lurbinectedin in Europe and the U.S. The company also saw a 22% rise in net sales and a 16% increase in royalty income. Despite a decrease in R&D investment, the financial results reflect positive growth in the oncology segment, with implications for sustained market presence and stakeholder confidence.
Pharma Mar, S.A. has announced the convening of its Ordinary General Meeting of Shareholders, scheduled for June 18, 2025. Key agenda items include the approval of the Annual Accounts, Management Reports, and a proposal for a dividend distribution. The meeting will also address the re-election of a director, authorization for share acquisitions, and a new share delivery plan for employees, reflecting the company’s strategic focus on governance and stakeholder engagement.
Pharma Mar SA has reported on its recent share buy-back program activities conducted between April 14 and April 17, 2025. The company purchased a total of 1,600 shares at the BME trading center, with weighted average prices ranging from 75.00000 to 75.62000 per share, as part of its ongoing efforts to stabilize and manage its treasury stock.